NRx Pharmaceuticals, Inc.
General ticker "NRXP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $44.3M (TTM average)
NRx Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 8.3%.
Estimated limits based on current volatility of 3.0%: low 2.44$, high 2.58$
Factors to consider:
- Total employees count: 3 as of 2017
- Top business risk factors: Insufficient funding, Regulatory and compliance, Limited operating history, Dependence on product success, Geopolitical risks
- Price in estimated range
- Earnings for 12 months up through Q4 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.79$, 3.44$]
- 2025-12-31 to 2026-12-31 estimated range: [0.75$, 3.22$]
Financial Metrics affecting the NRXP estimates:
- Positive: with PPE of -0.8 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -63.33 <= 0.07
- Positive: Investing cash flow per share per price, % of 0 > -0.65
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: Shareholder equity ratio, % of -636.07 <= 19.49
Short-term NRXP quotes
Long-term NRXP plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $1.23MM |
| Operating Expenses | $27.84MM | $19.70MM | $17.45MM |
| Operating Income | $-27.84MM | $-19.70MM | $-16.22MM |
| Non-Operating Income | $-2.31MM | $-5.42MM | $-12.40MM |
| Interest Expense | $0.12MM | $1.08MM | $0.67MM |
| R&D Expense | $13.37MM | $6.20MM | $3.78MM |
| Income(Loss) | $-30.15MM | $-25.13MM | $-28.62MM |
| Profit(Loss)* | $-30.15MM | $-25.13MM | $-28.62MM |
| Stockholders Equity | $-11.73MM | $-23.22MM | $-15.94MM |
| Assets | $7.32MM | $3.65MM | $12.96MM |
| Operating Cash Flow | $-21.66MM | $-10.64MM | $-14.11MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.00MM | $0.00MM | $-2.81MM |
| Financing Cash Flow | $6.20MM | $7.49MM | $23.28MM |
| Earnings Per Share** | $-3.98 | $-2.39 | $-1.34 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.